AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 May 2026 03:00 PM
RNS
Total Voting Rights and Admission of Shares
01 May 2026 07:05 AM
RNS
FDA ODAC vote on camizestrant in breast cancer
01 May 2026 07:00 AM
RNS
FDA ODAC recommends Truqap in prostate cancer
29 Apr 2026 07:00 AM
RNS
1st Quarter Results
28 Apr 2026 07:00 AM
RNS
Breztri approved in the US for asthma
27 Apr 2026 07:00 AM
RNS
Saphnelo self-administration approved in the US
23 Apr 2026 07:00 AM
RNS
Directorate change
21 Apr 2026 07:00 AM
RNS
I CAN PhIII interim analysis met primary endpoint
20 Apr 2026 07:00 AM
RNS
Third tozorakimab positive Phase III in COPD
09 Apr 2026 05:15 PM
RNS
Result of AGM
02 Apr 2026 07:00 AM
RNS
Imfinzi+Imjudo improves PFS in early liver cancer
01 Apr 2026 03:00 PM
RNS
Total Voting Rights and Admission of Shares
31 Mar 2026 07:00 AM
RNS
Efzimfotase alfa Ph3 program show positive results
27 Mar 2026 07:00 AM
RNS
Tozorakimab met OBERON/TITANIA primary endpoints
20 Mar 2026 11:00 AM
RNS
Notification of Admission of Shares
16 Mar 2026 07:00 AM
RNS
Imfinzi approved in EU for early gastric cancer
10 Mar 2026 11:00 AM
RNS
Notice of AGM
06 Mar 2026 11:10 AM
RNS
Director/PDMR Shareholding
06 Mar 2026 11:05 AM
RNS
Director/PDMR Shareholding
06 Mar 2026 11:00 AM
RNS
Director/PDMR Shareholding
02 Mar 2026 03:00 PM
RNS
Total Voting Rights
26 Feb 2026 07:00 AM
RNS
AstraZeneca prices a $2bn bond offering
25 Feb 2026 07:00 AM
RNS
Filing of Form 20-F with SEC
24 Feb 2026 11:00 AM
RNS
Annual Financial Report
24 Feb 2026 07:00 AM
RNS
Directorate change
20 Feb 2026 07:00 AM
RNS
Fixed-duration Calquence combo approved in US
10 Feb 2026 07:00 AM
RNS
Final Results
03 Feb 2026 07:00 AM
RNS
Update on Saphnelo subcutaneous administration
02 Feb 2026 03:00 PM
RNS
Total Voting Rights
02 Feb 2026 07:05 AM
RNS
Imfinzi recommended in EU for early gastric cancer
02 Feb 2026 07:00 AM
RNS
AstraZeneca begins trading on NYSE
30 Jan 2026 07:00 AM
RNS
AstraZeneca agrees obesity and T2D deal with CSPC
29 Jan 2026 09:51 AM
RNS
AstraZeneca invests $15bn in China through 2030
20 Jan 2026 07:00 AM
RNS
AstraZeneca to complete direct listing on NYSE
08 Jan 2026 07:00 AM
RNS
AZN new Head of Investor Relations Joris Silon
02 Jan 2026 03:00 PM
RNS
Total Voting Rights
22 Dec 2025 11:00 AM
RNS
Director/PDMR Shareholding
22 Dec 2025 07:30 AM
RNS
Enhertu granted BTD for post-neoadjuvant early BC
22 Dec 2025 07:00 AM
RNS
Update on LATIFY Phase III trial of ceralasertib
19 Dec 2025 11:00 AM
RNS
Director/PDMR Shareholding
16 Dec 2025 07:05 AM
RNS
Subcutaneous Saphnelo approved in EU
16 Dec 2025 07:00 AM
RNS
Enhertu approved in US for 1L HER2+ metastatic BC
04 Dec 2025 03:00 PM
RNS
Holding(s) in Company
01 Dec 2025 03:05 PM
RNS
Block listing Interim Review
01 Dec 2025 03:00 PM
RNS
Total Voting Rights
26 Nov 2025 07:00 AM
RNS
Imfinzi approved in US for early gastric cancer
24 Nov 2025 07:00 AM
RNS
AstraZeneca manufacturing investment in Maryland
20 Nov 2025 07:00 AM
RNS
Koselugo (selumetinib) approved in the US
17 Nov 2025 03:00 PM
RNS
Holding(s) in Company
14 Nov 2025 11:00 AM
RNS
Director/PDMR Shareholding

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings